BRIEF published on 01/19/2026 at 07:35, 5 months 1 day ago Advicenne: FDA-approved marketing application for Sibnayal® FDA ATRd Advicenna Sibnayal® PDUFA
PRESS RELEASE published on 01/19/2026 at 07:30, 5 months 1 day ago Inside Information / Other news releases FDA accepts Advicenne's Marketing Authorization Application for Sibnayal® for dRTA treatment in the US, with a PDUFA decision target date of September 3rd, 2026 FDA Advicenne Sibnayal DRTA PDUFA
BRIEF published on 01/12/2026 at 07:35, 5 months 8 days ago Renewal of the marketing authorization for Sibnayal® in the European Union Kidney Disease EMA Advicenna AMM Sibnayal®
BRIEF published on 11/04/2025 at 11:35, 7 months 16 days ago Advicenne submits Sibnayal® to the US FDA FDA Advicenna Sibnayal® Renal Tubular Acidosis Registration Filing
PRESS RELEASE published on 11/04/2025 at 11:30, 7 months 16 days ago Inside Information / Other news releases Advicenne submits registration application for Sibnayal® in dRTA treatment to US FDA, designated orphan drug. Evaluation process expected to take 12 months Advicenne Sibnayal® US FDA DRTA Treatment Registration Application
BRIEF published on 09/19/2025 at 18:05, 9 months 1 day ago Advicenne: Half-year results in 2025 and outlook Financial Results Outlook Turnover United States Sibnayal®
BRIEF published on 07/28/2025 at 07:35, 10 months 23 days ago Advicenne Secures Marketing Authorization for Sibnayal® in Saudi Arabia Saudi Arabia Advicenne Reimbursement Sibnayal® DRTA
PRESS RELEASE published on 07/28/2025 at 07:30, 10 months 23 days ago Inside Information / Other news releases Advicenne obtains marketing authorization and reimbursement for Sibnayal® in Saudi Arabia, a fixed combination for rare kidney diseases, in collaboration with Taïba Healthcare Saudi Arabia Advicenne Reimbursement Marketing Authorization Sibnayal
BRIEF published on 07/25/2025 at 07:35, 10 months 26 days ago Advicenne Announces 9% Revenue Growth for H1 2025 Growth Turnover Advicenna Sibnayal® Pharmaceutical Markets
PRESS RELEASE published on 07/25/2025 at 07:30, 10 months 26 days ago Inside Information / Other news releases Advicenne reports H1 2025 sales of €2.6 million, with direct sales rising 17% and Sibnayal® sales in Europe up 90% compared to H1 2024. Company's cash flow horizon extends to Q3 2026 Cash Flow Pharmaceutical Advicenne Sibnayal H1 2025 Sales
Published on 06/20/2026 at 00:00, 20 hours ago Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development
Published on 06/19/2026 at 04:30, 1 day 15 hours ago Uraniumx Discovery Corp. Announces Acquisition of Common Shares of Gold'n Futures Mineral Corp
Published on 06/19/2026 at 01:20, 1 day 18 hours ago American Hotel Income Properties REIT LP Reports Voting Results of Annual and Special Meeting
Published on 06/19/2026 at 01:07, 1 day 18 hours ago Usha Resources Announces Share Issuance in Payment of Debenture Interest, Adopts Semi-Annual Reporting
Published on 06/20/2026 at 06:00, 14 hours ago Successful debut of International Symposium on Emergency Response and Aeromedical Services in Hong Kong
Published on 06/19/2026 at 20:17, 23 hours 42 minutes ago 2CRSi SA: 2CRSi Responds Point-by-Point to the Grizzly Research Report and Reaffirms the Reality of Its Business Operations
Published on 06/19/2026 at 19:01, 1 day ago Fuller, Smith & Turner PLC: Publication of the Annual Report and Accounts for the 52 weeks ending 28 March 2026 and Notice of 2026 Annual General Meeting
Published on 06/19/2026 at 19:33, 1 day ago Disclosure of transactions in own shares from June 15 to June 19, 2026
Published on 06/19/2026 at 19:23, 1 day ago Imerys-06-2026-information-share-capital-and-voting-rights-as-of-31-May-2026
Published on 06/18/2026 at 18:00, 2 days 2 hours ago Outstanding shares and voting rights statement at 31 May 2026
Published on 06/18/2026 at 17:45, 2 days 2 hours ago EURAZEO INVESTS IN LAURALU, A PAN-EUROPEAN PROVIDER OF DEPLOYABLE INDUSTRIAL INFRASTRUCTURE
Published on 06/18/2026 at 17:38, 2 days 2 hours ago Statement of transactions in own shares from June 8, 2026 to June 12, 2026
